Edit |   |
---|---|
Antigenic Specificity | PDCD1/PD-1/CD279 (Camrelizumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Camrelizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD-1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy). |
Immunogen | n/a |
Other Names | Camrelizumab, PDCD1/PD-1/CD279, 1798286-48-2 |
Gene, Accession # | CAS: 1798286-48-2 |
Catalog # | abx831403 |
Price | please inquire |
Order / More Info | PDCD1/PD-1/CD279 (Camrelizumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950